Molecular structure of Alrestatin, CAS Number: 51411-04-2
Alrestatin (CAS 51411-04-2)
Application:
Alrestatin is an AKR inhibitor
CAS Number:
51411-04-2
Purity:
≥99%
Molecular Weight:
255.2
Molecular Formula:
C14H9NO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Alrestatin is an AKR (aldose reductase) inhibitor, which attaches molecules to the active site of the NADP+/enzyme complex in a stacked formation. Studies conducted on diabetic models suggest that Alrestatin inhibits the mean basal insulin level. Alrestatin suppresses the accumulation of cAMP which is induced by prostaglandin E2. Theses studies indicate that Alrestatin can be essential in studying variations in hormone release caused by cAMP accumulation. Alternatively, Alrestatin has been shown to inhibit the formation of cataracts in lenses via the sorbitol pathway. In rats Alrestatin inhibits gastric juice production in the pylorus-ligated rat when it is administered intraperitoneally.
Alrestatin (CAS 51411-04-2) References
- Alrestatin: gastric acid antisecretory-antiulcer activity in the rat. | Lippmann, W., et al. 1978. Digestion. 18: 35-44. PMID: 103765
- Efficacy of Alrestatin, an aldose reductase inhibitor, in human diabetic and nondiabetic lenses. | Chylack, LT., et al. 1979. Ophthalmology. 86: 1579-85. PMID: 121768
- Neonicotinoid insecticides: reduction and cleavage of imidacloprid nitroimine substituent by liver microsomal and cytosolic enzymes. | Schulz-Jander, DA., et al. 2002. Chem Res Toxicol. 15: 1158-65. PMID: 12230409
- Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. | Lavrentyev, EN., et al. 2007. Circ Res. 101: 455-64. PMID: 17626897
- Inhibition of prostaglandin-induced cyclic AMP accumulation in the rat anterior pituitary by alrestatin. | Lippmann, W. 1978. Experientia. 34: 441-3. PMID: 205429
- The medicinal chemistry of aldose reductase inhibitors. | Humber, LG. 1987. Prog Med Chem. 24: 299-343. PMID: 3144023
- Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. | Hotta, N., et al. 1985. Diabetologia. 28: 176-80. PMID: 3922829
- Human placenta aldose reductase. Forms sensitive and insensitive to inhibition by alrestatin. | Maragoudakis, ME., et al. 1984. Mol Pharmacol. 25: 425-30. PMID: 6427599
- The effect of alrestatin on alanine-stimulated release of insulin and glucagon in man. | Distiller, LA., et al. 1981. J Endocrinol Invest. 4: 115-7. PMID: 6787107
- Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil. | O'Brien, MM., et al. 1982. J Neurochem. 39: 810-4. PMID: 6808090
- Effect of alrestatin sodium on glucose-stimulated insulin secretion in the fasted anaesthetized rat. | Kobric, M. and Lippmann, W. 1978. Horm Metab Res. 10: 495-500. PMID: 744568
- Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors. | Ehrig, T., et al. 1994. Biochemistry. 33: 7157-65. PMID: 8003482
- Effect of alrestatin on arginine-induced secretion of glucagon and insulin in the rat. | Lippmann, W. and Kobric, M. 1978. Horm Metab Res. 10: 280-2. PMID: 98419
Inhibitor of:
β-Galactose Dehydrogenase, AKR, AKR7A4, Aldose Reductase, Enzyme, GPT, and TGase6.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Alrestatin, 10 mg | sc-201443 | 10 mg | $113.00 | |||
Alrestatin, 50 mg | sc-201443A | 50 mg | $510.00 |